IPO Fri­day: Hy­per­ten­sion drug­mak­er Min­eralys maps out $192M Nas­daq de­but

Wall Street is wel­com­ing a new drug de­vel­op­er to the stock mar­kets for the sec­ond Fri­day in a row.

Min­eralys Ther­a­peu­tics said Thurs­day night its ini­tial pub­lic of­fer­ing had priced at $16 per share, the high end of its pro­posed range, with an ex­pect­ed $192 mil­lion in pro­ceeds.

The biotech, near­ing a Phase III for its lead as­set, joins a small club of drug de­vel­op­ers that has jumped on­to the pub­lic mar­kets re­cent­ly af­ter the IPO door ap­peared to slam shut last win­ter.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER